Akèy › Kansè poumon › New York › New York City
Etid klinik pou Kansè poumon nan New York City, NY
60 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of ZW251 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mental Health Care in People With Cancer
Ap rekrite
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Ap rekriteFaz 3
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Empathic Communication Skills (ECS) Training
Ap rekriteVolontè an sante akeyi
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Memorial Sloan Kettering Hospital, New York
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- NYU Langone's Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center, New York
A Registry for People With Lung Cancer
Ap rekriteEtid obsèvasyon
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Ap rekriteFaz 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Memorial Sloan Kettering Cancer Center, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Laura and Isaac Perlmutter Cancer Center, New York
- Manhattan Eye, Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, New York
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Perlmutter Cancer Center - NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Ap rekriteFaz 3
- Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Ap rekriteFaz 1
- New York Cancer & Blood Specialists, New York
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- New York Proton Center, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- ak 1 plis
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- New York Proton Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Lung Cancer Risk
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Ap rekriteFaz 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Ap rekrite
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- New York University Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 2
- New York University Langone Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- NYU Langone Medical Center, New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Ap rekriteFaz 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, New York
- Research Site, New York
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Ap rekriteFaz 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
Ap rekriteFaz 1
- Columbia University Irving Medical Center, New York
Lung Cancer Biomarkers and Screening
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NYU Cancer Institute at New York University Medical Center, New York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Ap rekriteFaz 2
- Weill Cornell Medicine, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Confocal Laser Endomicroscopy VERification
Ap rekrite
- Montefiore Medical Center, New York
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Ap rekriteEtid obsèvasyon
- Manhattan Eye Ear and Throat Hospital, New York
- Lenox Hill Hospital, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- Weill Cornell Medicine, Cornell University (site 126), New York
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
Ap rekriteEtid obsèvasyon
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- NYU Langone Health, New York
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
Ap rekriteFaz 2
- NYU Langone Health, New York
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Ap rekriteEtid obsèvasyon
- Icahn School of Medicine at Mount Sinai, New York
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- Memorial Sloan Kettering Cancer Center, New York
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- Los Angeles, CA45 etid
- Arlington, VA41 etid
- Washington, DC41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
- Seattle, WA33 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
- Ensifizyans kadyak51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.